| Company/Division name | H. Lee Moffitt Cancer Center & Research Institute |
| Type of work | Manufacturing |
| If manufacturing, is the company a contract manufacturer? | Yes |
| Reshoring category: | Reshoring |
| Total number of jobs (added or to be added): | 14500 |
| Year reshoring announced: | 2021 |
| Year reshoring implemented or to be implemented: | 2026 |
| Domestically, the work will be done: | In-house |
| State(s) reshored to: | FL |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals, Life Sciences, biotech |
| Product(s) reshored | pharmaceuticals, cancer drugs |
| What domestic positive factors made reshoring more attractive? | Government Incentives, Under-utilized capacity, Other, import replacement |
| Government Incentive dollar amount: | $25 million |
